The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 3, 2009, Pages 298-304

  Shlay, Judith C ^a,e   Sharma, Shweta ^b   Peng, Grace ^b   Gibert, Cynthia L ^c   Grunfeld, Carl ^d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DENVER PUBLIC HEALTH   (United States)

Author keywords

Adverse effects; Antiretroviral drugs; Body composition; HIV; Lipodystrophy

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARM; ARTICLE; BODY COMPOSITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SKINFOLD THICKNESS; SUBCUTANEOUS TISSUE; THIGH; WAIST CIRCUMFERENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY COMPOSITION; FEMALE; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS;

EID: 67651015689     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181aa1308     Document Type: Article

References (36)

1. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
2. Gervasoni C, Ridolfo A, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999; 13:465-472.
3. Madge S, Kinloch-DeLoes S, Tyrer M, et al. Lipodystrophy in patients naive to protease inhibitors. AIDS. 1999;13:735-737.
4. Dube M, Parker R, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS. 2005; 19:1807-1818.
5. Shlay J, Visnegarwala F, Bartsch G, et al. Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr. 2005;38:147-155.
6. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001; 15:1389-1398.
7. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA. 2002; 288:207-215.
8. Bogner JR, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
9. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
10. Jemsek J, Arathoon E, Arlotti M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral naive HIV-infected patients. Clin Infect Dis. 2006;42:273-280.
11. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr. 2006;44:139-147.
12. Bacchettti P, Gripshoever B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr. 2005;40:121-131.
13. From the Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr. 2006;42:562-571.
14. Shlay J, Sharma S, Peng G, et al. Long-term subcutaneous tissue changes among antiretroviral naïve persons initiating stavudine, zidovudine, or abacavir with lamivudine. J Acquir Immune Defic Syndr. 2008;48:53-62.
15. Shlay J, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral-naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr. 2007;44:506-517.
16. MacArthur R, Chen L, Mayer D, et al. The rationale and design of the CPCRA (Terry Beirn Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 2001;22:139-141.
17. MacArthur R, Novak R, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): a long-term randomised trial. Lancet. 2006;368: 2125-2135.
18. Wang J, Bartsch G, Raghavan S, et al. Reliability of body composition and skinfold measurements by observers trained in groups. Int J Body Compos Res. 2004;2:31-36.
19. Lohman TG, Roche A, Martorell R. Anthropometric Standard Reference Manual. Champaign, IL: Human Kinectics; 1988.
20. Wang J, Thorton J, Kolesnik S, et al. Anthropometry in body composition: an overview. Ann N Y Acad Sci. 2000;904:317-326.
21. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228-237.
22. Wang J, Thorton J, Russell M, et al. Asians have lower body mass index (BMI) but higher percent body fat than do whites: comparisons of anthropometric measurements. Am J Clin Nutr. 1994;60:23-28.
23. Kotler DP, Burastero S, Wang J, et al. Prediction of body cell mass, fat-free mass and total body water with bioelectrical bioimpedance analysis: effects of race, gender and disease. Am J Clin Nutr. 1996;64(Suppl 3):489-497.
24. Brown T, Xiuhong L, Cole S, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375-1383.
25. John M, McKinnon E, James I, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr. 2003;33:29-33.
26. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX extension study. AIDS. 2004;18:1029-1036.
27. Moyle G, Baldwin B, Landroudi B, et al. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. J Acquir Immune Defic Syndr. 2003;33:22-28.
28. Drechsler H, Powderly WG. Switching effective antiretroviral therapy: a review. Clin Infect Dis. 2002;35:1219-1230.
29. Dube M, Komarow L, Mulligan K, et al. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides: dual X-ray absorptiometry results from A5005S, a substudy of Adult Clinical Trials Group 384. J Acquir Immune Defic Syndr. 2007;45:508-514.
30. Mallon PWG, Miller J, Cooper D, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979.
31. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. Geneva, Switzerland: World Health Organization; 2006.
32. Wang J, Kotler D, Russell M, et al. Body-fat measurement in patients with acquired immunodeficiency syndrome: which method should be used? Am J Clin Nutr. 1992;56:963-967.
33. Knox T, Zafonte-Sanders M, Fields-Gardner C, et al. Assessment of nutritional status, body composition, and human immunodeficiency virus-associated morphologic changes. Clin Infect Dis. 2003;36(Suppl 2): S63-S68.
34. Mulligan K, Parker R, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr. 2006;41: 590-597.
35. He Q, Wang J, Engelson E, et al. Ability of an anthropometric model to track changes in subcutaneous adipose tissue area. FASEB J. 2002; 16 (5-II):A1024-A1025.
36. Scherzer R, Wei S, Bacchetti P, et al. Simple anthropometric measures correlate with metabolic risk indicators as strongly as magnetic resonance imaging - measured adipose tissue depots in both HIV-infected and control subjects. Am J Clin Nutr. 2008;87:1809-1817.